Metalyse 40 mg Contraindications

METALYSE is contraindicated in: patients with known hypersensitivity to the active substance tenecteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients.
Situations associated with a risk of bleeding such as: significant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesis; patients receiving effective oral anticoagulant treatment, e.g. warfarin sodium (INR >1.3) (see Bleeding under Precautions); any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery); severe uncontrolled arterial hypertension; major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current AMI), recent trauma to the head or cranium; prolonged or traumatic cardiopulmonary resuscitation (>2 minutes) within the past 2 weeks; severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; active peptic ulceration; arterial aneurysm and known arterial/venous malformation; neoplasm with increased bleeding risk; acute pericarditis and/or subacute bacterial endocarditis; acute pancreatitis; haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months.